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Abstract 
 
It is well documented that HLA-Cw6+ (type 1) psoriasis patients have increased 
severity and reduced age of onset of psoriasis. However, not much is known 
about any differential response of this genetic subgroup to various treatments. 
We set out to determine if there was any genetic association of the HLA-Cw6 
allele with the first-line systemic treatment commonly used in psoriasis, 
methotrexate. A cohort of patients from Tayside, Scotland was recruited through 
a novel generic consenting process (GoShare), extensively phenotyped, and 
analysed for an association of their HLA-Cw6 genotype status with treatment 
outcomes. HLA-Cw6+ patients showed notably improved response to 
methotrexate (p = 0.05), and further analysis demonstrates an even greater 
response in a sub-cohort of the HLA-Cw6+ patients without concomitant 
psoriatic arthritis (p = 0.01). HLA-Cw6+ patients also exhibited fewer treatment 
limiting adverse events. In addition to these findings, the methodology and 
primary clinical outcome phenotype, which we validate here, will greatly 
facilitate replication of the present results in independent cohorts.   
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Introduction 
Pharmacogenomics for genetic diseases has been identified as a future area of 
knowledge growth 1 but data have been sparse. For a common genetic disease, 
psoriasis, and a very common treatment, methotrexate, few pertinent data have 
been published 2.  
One limitation for population-based pharmacogenomics has been availability of 
good phenotypic data and limitations around patient consent. To address these 
limitations, we have recently established a novel generic approach to 
consenting entitled GoShare (www.goshare.org.uk) whereby patients consent to 
use of residual blood samples taken in routine practice for research. This allows 
rapid and inexpensive establishment of patient cohorts. 
Apart from cohort assembly, description of phenotypes with low selection and 
reporting bias is another limitation in pharmacogenomics approaches. In this 
regard electronic capture available in Tayside allows for near-complete 
phenotype collection regarding medical treatments and outcomes in a 
population size of 450000. These resources have allowed the recent in-depth 
phenotyping of the largest population-based cohort of psoriasis patients treated 
with methotrexate to date 3. 
We here report the first GoShare consented sub-cohort of the Tayside 
methotrexate treatment cohort 3 and report efficacy and safety outcomes for 
methotrexate treatment based on HLA-Cw6 status, which identifies two 
established genetic psoriasis subgroups and is also genetically associated with 
psoriasis arthritis 4.   
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Report 
Establishment of a cohort of MTX-treated psoriasis patients for genetic 
analysis. Detailed methods are supplied in the Supplement. The overall clinical 
characteristics of the HLA-test cohort and parent cohort are very similar (Table 
1). Furthermore, the overall treatment outcome over a period of ten years 
shows similar rates of MTX discontinuation for both lack of efficacy and 
treatment limiting AEs in both the HLA-test and the parent cohorts (Fig 1a). 
Finally, the spectrum of treatment limiting AEs in the HLA-test cohort is largely 
in line with the parent cohort (Table S2). We conclude that sampling bias 
introduced by GoShare cohort building is minimal and that results obtained by 
genotyping of the HLA-test cohort are likely to be representative of the parent 
cohort.  
 Clinical characteristics of the cohort by HLA-C genotype. The clinical 
characteristics of the HLA-Cw6 genotyped cohort are shown in Table 2. As 
expected, the HLA-Cw6 positive cohort exhibits a lower median age of onset of 
disease, consistent with “type 1 psoriasis” 5. However, both subgroups differ in 
the prevalence of concurrent psoriatic arthritis wherefore this potential 
confounder was addressed in further analysis (see below).  
Improved response to methotrexate treatment in HLA-Cw6+ patients. We 
previously validated the outcome “treatment duration beyond 12 months” as a 
proxy for treatment efficacy in the parent cohort 3. We were able to verify the 
same in the HLA-test cohort (Fig S1). The outcome “on treatment > 1 year” was 
therefore analysed stratified by HLA-C status. As shown in Fig 1b, four-fifths of 
treatment episodes for the HLA-Cw6 positive group were carried on beyond 12 
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months, compared with only two-thirds of treatment episodes for the HLA-Cw6 
negative group (p = 0.05). As evident from the figure, both lack of efficacy and 
limiting adverse effects occur with higher frequency in the HLA-Cw6-negative 
subgroup and contribute to the overall poorer response to treatment.  
HLA-Cw6-status is highly predictive of response to MTX treatment in 
psoriasis patients without concomitant arthritis. Since the prevalence of patients 
with arthritis was unevenly distributed between the HLA-Cw6+ and HLA-Cw6- 
cohorts, treatment outcome in both subgroups was analysed after eliminating 
patients with concomitant psoriatic arthritis. The results are shown in Fig 1b 
(lower panels). Strikingly, despite the resultant smaller cohort size, the 
treatment outcomes were even more significantly affected by HLA-Cw6 status 
with regard to the number of patients reaching treatment duration of 1 year. 
Thus, 80% of HLA-Cw6+ patients reach 1 year of treatment compared to 51% 
of HLA-Cw6- patients (p = 0.01, exact test mid p value).  
As an independent treatment outcome, the effect of methotrexate in 
those patients, who do achieve one year of treatment duration, on the usage of 
psoriasis – targeted topical treatments was also analysed, as shown in Fig 1c. 
There was a greater reduction in prescriptions made out for HLA-Cw6+ patients 
after methotrexate treatment. Again, this effect was more pronounced, and 
highly statistically significant in the arthritis-free subgroup. These data indicate 
that – not only do more HLA-Cw6+ patients show an overall response to 
methotrexate but, in addition, those who do respond, appear to achieve better 
disease control. 
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Discussion 
The current data show that the response of psoriasis patients to 
treatment with methotrexate appears to be influenced by genetic subtype. HLA-
Cw6 positive patients (largely overlapping with type 1 psoriasis) have a better 
chance of responding, and fewer appear to develop adverse effects than HLA-
Cw6 negative patients. Although the size of our sample is the principle limitation 
of our findings, the sample still is significantly larger than that recently reported 
to substantiate a genetic association of HLA-Cw6 status with response to 
ustekinumab treatment in psoriasis 6. In general, pharmacodynamic studies on 
the effect of HLA-Cw6 status on treatment response in psoriasis are scarce. A 
recent medium-size study did not find any effect on the response to anti-TNF 
treatment 7. 
The large observed effect size (threefold reduction in primary lack of 
efficacy among HLA-Cw6+ patients) would certainly appear large enough to 
warrant replication studies. To that end, the inexpensive methodology (single 
SNP genotyping) and the validated, and widely available primary clinical 
phenotype endpoint we here provide (“on treatment > 1 year”) should prove 
very useful in real-world cohorts where formal outcomes such as PASI are 
rarely available. 
 It is unclear why the effect of HLA-Cw6 status should be more 
pronounced in patients without concomitant arthritis. Certainly, the effect could 
be spurious, given the moderate sample size. Alternatively, the presence of 
systemic inflammatory arthritis itself may well affect not only psoriasis severity 
but also response to treatment. In that regard, the response rate to 
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methotrexate has recently been shown to be a associated to another genetic 
marker (KIR2DS4 alleles) in rheumatoid arthritis 8. The genetic association of 
HLA-Cw6 with the response of psoriasis arthritis as such to methotrexate has 
not been reported to date. 
In addition to genetic psoriasis subgroups, genetic heterogeneity in 
genes regulating methotrexate metabolism may affect treatment outcome in 
psoriasis, as has been shown rheumatoid arthritis 9, 10. Although MTX-related 
genes variants have not been shown to be predictive of clinical outcomes in a 
previous study 11, regulatory SNPs for these and other genes remain to be 
tested. We were unable to address these issues here, as our sample size 
precluded multiple testing.  
The ability to rapidly assemble cohorts for association studies using a 
generic consenting approach in conjunction with complete phenotype access 
through the availability of electronic database (detailed in 3) offers considerable 
potential to advance pharmacogenomics research, especially under real-world 
conditions, complementing data on methotrexate efficacy gathered in clinical 
trials 12.  
In conclusion, we here report that HLA-Cw6+ (type 1) subgroup of 
psoriasis patients exhibit a significantly better response to methotrexate 
treatment. If confirmed in larger replication cohorts, this may lead to validation 
of an inexpensive predictive blood test helpful for clinical decision making. 
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Tables 
Table 1. Comparison of HLA-test cohort and parent cohort1 
 Parent cohort HLA-C sub cohort 
 n = 333 % n = 70 % 
General Characteristics:   
Female 195 59 41 59 
Age at onset of disease < 41 
(years) 
200 60 41 59 
Median age at start MTX (range)2 48 (9 - 85)  49 (16 - 77)  
Median disease duration prior to 
MTX (range)  
12.5 (0 - 23)  13 (0 - 23)  
Psoriasis treatment history:   
Prior UVB 263 79 56 80 
Prior PUVA 189 57 38 54 
Prior Topical treatments3 323 97 70 100 
Prior Acitretin 47 14 12 17 
Comorbidities:   
Diabetes4 29 9 7 10 
Hypertension 65 20 14 20 
Concomitant PsA5 81 24 21 30 
1Data shown summarise clinical profile accessible through electronic data mining as 
detailed in Methods. Abbreviations: MTX - methotrexate; UVB - ultraviolet B; PUVA - 
psoralen combined with ultraviolet A; PsA - psoriatic arthritis. 
2Five of the total cohort and one of the HLA sub-cohort were started on MTX treatment 
under 18 years of age. 
3Topicals include agents containing steroids, calcipotriol, coal tar, dithranol, retinoids, 
salicylic acid but no emollients.  
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4Diabetes. From the 29 diabetes patients in the parent cohort the diagnosis were: 27 
type 2 diabetes, 1 type 1 diabetes and 1 patient with impaired glucose tolerance. All of 
the 7 patients in the HLA-cohort were diagnosed with type 2 diabetes. 
5See Methods on definition used for PsA. 
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Table 2. Clinical characteristics of the HLA-Cw6 positive and HLA-Cw6 negative 
cohorts1 
 HLA-Cw6 positive HLA-Cw6 negative 
 n = 27 % n = 43 % 
General Characteristics:   
Female 18 67 23 53 
Age at onset of disease < 41 
(years) 
18 67 23 53 
Median age at start MTX (range)2 44 (16 - 77)  51 (24 - 76)  
Median disease duration prior to 
MTX (range)  
14 (0 - 21)  11 (0 - 23)  
Psoriasis treatment history:   
Prior UVB 24 89 32 74 
Prior PUVA 18 67 20 47 
Prior Topical treatments3 27 100 43 100 
Prior Acitretin 5 19 7 16 
Comorbidities:   
Diabetes4 2 7 5 12 
Hypertension 6 22 8 19 
Concomitant PsA5 5 19 16 37 
1Data shown summarise clinical profile accessible through electronic data mining as 
detailed in Methods. Abbreviations: MTX - methotrexate; UVB - ultraviolet B; PUVA - 
psoralen combined with ultraviolet A; PsA - psoriatic arthritis. 
2One of the patients in the HLA-Cw6 negative patients was initiated on methotrexate 
therapy below 18 years of age.  
3Topicals include agents containing steroids, calcipotriol, coal tar, dithranol, retinoids, 
salicylic acid but no emollients.  
4All of the seven patients with diabetes had a diagnosis of type 2 diabetes. 
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5See Methods on definition used for PsA. 
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Legend to Figure  
 
Figure 1 - A. Data show the percentage of patients discontinued due to lack of 
efficacy (left) and treatment limiting AEs (right) over a treatment period of 10 
years. B. The number of patients on continued treatment and those 
discontinued due to either lack of efficacy or MTX related toxicity at 12 months 
of treatment for HLA-Cw6 positive patients (left) and HLA-Cw6 negative patients 
(right). “Toxicity” - any treatment limiting adverse effect. Upper panels show all 
patients, and lower panels those without concomitant psoriatic arthritis, as 
indicated. C. The percentage of patients who achieved a reduction in the 
number of psoriasis specific prescriptions after one year of successful MTX 
treatment among the whole HLA-test cohort (left) and psoriasis patients without 
concomitant psoriatic arthritis (right), respectively. * p < 0.05 (exact test mid-p 
value).  
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